

<i>List of Tables and Figures</i>	xiii
<i>List of Contributors</i>	xv
<i>List of Acronyms</i>	xvii

1. The Pharmaceutical Industry and Access to Medicines in India	1
<i>Hans Löfgren</i>	
The Pre-1972 Product Patent Period	7
The Process Patent Era 1972–2005	10
Full TRIPS-compliance from 2005	12
Financial and Economic Crisis and Access to Medicines for All	17
2. Challenges of Regulation of Medicines in India	24
<i>S. Srinivasan and Anant Phadke</i>	
Price Regulation	25
Weeding Out of Irrational Medicines: A Necessary Complement to Price Control	31
Law on Banning Irrational Medicines	35
Towards Ethical Marketing and Promotion of Medicines	38
Promoting Transparency and Declarations of Conflict of Interest	40
General Review of all Legislations	41
Other Issues	42
Conclusion	48

3. CIPLA: Patients before Patents	55
<i>Neelam Raaj</i>	
Modest Beginnings	56
Yusuf Hamied Living up to his Legacy	57
India's Patent Law 1972	58
The Three Drug Combination: Potent Cocktail	58
A Life-saving Offer	59
Success Story	62
The Road Ahead	63
4. Systemic Failure of Regulation: The Political Economy of Pharmaceutical and Bulk Drug Manufacturing	73
<i>G. Vijay</i>	
The Regulation of Industrial Pollution	75
Structure and Methodology	80
Structures of the Value Chains in the Rural Economy	82
Pathways of Pollution in the Dairy Industry	83
Regulatory Checks on Pathways in Value Chains	87
Final Observations	97
5. TRIPS Flexibilities and Access to Patented Medicines in India	108
<i>Narayanan Lalitha</i>	
Use of Trips Flexibilities	109
Exemptions from Patentability	109
Future Options	126
6. India's Free Trade Agreements: Implications for Access to Medicines in India and the Global South	134
<i>Kajal Bhardwaj</i>	
Introduction	134
TRIPS Compliance: Using the Doha Declaration in India	136
India's FTA Negotiations: An Overview	139
FTAs and Access to Medicines: Key Concerns	142
Intellectual Property Provisions	143
Investment (or Investor Protection) Measures	155
Regulatory Harmonization	159

Government of India's Position	160
FTAs, TRIPS and the Right to Health	161
Conclusion	164

## 7. At any Price? Boehringer Ingelheim, Bayer HealthCare and Baxter in India

*Christiane Fischer and Claudia Jenkes*

The Examined Companies	178
How Good are the Drugs Supplied by these Companies?	180
What about Access?	185
Drug Treatment in the NGO, Private and Public Sectors	187
Research and Patents	189
Marketing and Business Behaviour	190
Conclusion	193

## 8. Trends and Prospects for India as a Global Generic Player

*Deepak Kumar Jena and Poduri Balaram*

Introduction	198
Regulatory Status of India in World Generics Markets	199
India's Bilateral Trade in Pharmaceutical Products	207
Outlook for the Indian Pharmaceutical Industry	211
TRIPS and the Future of the Indian Pharmaceutical Industry	218
Conclusion	220

## 9. The Indian Patent Law and Access to Antiretroviral Drugs in Sub-Saharan Africa

*Christiane Fischer*

TRIPS and Public Health	226
Compulsory Licensing	227
Parallel Imports	229
The Scope of Patentability	230
Indian Patent Law	233
African Patent Laws	236
The Impact of the Patent Status in India on Access in Sub-Saharan Africa	236

Government of India's Position	160
FTAs, TRIPS and the Right to Health	161
Conclusion	164
7. At any Price? Boehringer Ingelheim, Bayer HealthCare and Baxter in India	176
<i>Christiane Fischer and Claudia Jenkes</i>	
The Examined Companies	178
How Good are the Drugs Supplied by these Companies?	180
What about Access?	185
Drug Treatment in the NGO, Private and Public Sectors	187
Research and Patents	189
Marketing and Business Behaviour	190
Conclusion	193
8. Trends and Prospects for India as a Global Generic Player	198
<i>Deepak Kumar Jena and Poduri Balaram</i>	
Introduction	198
Regulatory Status of India in World Generics Markets	199
India's Bilateral Trade in Pharmaceutical Products	207
Outlook for the Indian Pharmaceutical Industry	211
TRIPS and the Future of the Indian Pharmaceutical Industry	218
Conclusion	220
9. The Indian Patent Law and Access to Antiretroviral Drugs in Sub-Saharan Africa	225
<i>Christiane Fischer</i>	
TRIPS and Public Health	226
Compulsory Licensing	227
Parallel Imports	229
The Scope of Patentability	230
Indian Patent Law	233
African Patent Laws	236
The Impact of the Patent Status in India on Access in Sub-Saharan Africa	236

Lacking Access to Patented Radical Innovative Antiretrovirals	240
Patents Matter	241
10. Accessing Medicines in Developing Economies	248
<i>Tu Thanh Nguyen</i>	
Intersection between IPRs and Competition Law	251
Refusal to Licence Pharmaceutical Patents in South Africa	254
Some Considerations	258
Abbott's Withdrawal of Medicine Registration Applications in Thailand	262
Exclusive Distribution and the High Prices of Medicines in Vietnam	263
Indian Perspective	265
Concluding Remarks	267
11. The Politics of AIDS Treatment in Brazil	274
<i>André de Mello e Souza</i>	
Introduction	274
The Strategy of Local Generic Production	276
Challenges to the Sustainability of an Inclusive AIDS Treatment Policy	284
Restricting Patent Rights to Reduce ARV Costs	289
Conclusions	293
12. Financing Pharmaceutical Research and Development: Alternatives to the Patent System	302
<i>Philip Soos and Hans Löfgren</i>	
Problems with the Patent System	306
Alternative Mechanisms for Financing R&D	311
Conclusion	322
13. Post-script	
<i>Hans Löfgren</i>	328